利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.015 秒)

    Adaptive tree structure for visualizing data
    13.
    发明授权
    Adaptive tree structure for visualizing data 有权
    用于可视化数据的自适应树结构

    公开(公告)号：US08595750B2

    公开(公告)日：2013-11-26

    申请号：US12956127

    申请日：2010-11-30

    申请人： Mayank Agarwal ,  Alexander Dadiomov ,  Xinhua Ji

    发明人： Mayank Agarwal ,  Alexander Dadiomov ,  Xinhua Ji

    IPC分类号： G06F9/46

    CPC分类号： G06F9/542 ,  G06F17/30994

    摘要： One or more systems and/or techniques for generating an adaptive tree structure for storing event data based upon data density of events are disclosed. In particular, the adaptive tree structure may comprise one or more levels of nodes, where a level may correspond to a resolution of events. Nodes may correspond to particular time spans over which event data was recorded. A node may be designated as a raw node comprising raw events or a summary node comprising summary events based upon the number of events occurring within a time span covered by the node.

    摘要翻译： 公开了一种或多种用于基于事件的数据密度生成用于存储事件数据的自适应树结构的系统和/或技术。 特别地，自适应树结构可以包括一个或多个节点级别，其中级别可以对应于事件的分辨率。 节点可以对应于记录事件数据的特定时间跨度。 可以将节点指定为包括原始事件的原始节点或基于在该节点覆盖的时间范围内发生的事件的数量的包含摘要事件的摘要节点。

    O2-arylated or O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates and O2-substituted 1-[(2-carboxylato) pyrrolidin-1-yl] diazen-1-ium-1,2-diolates
    15.
    发明授权
    O2-arylated or O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates and O2-substituted 1-[(2-carboxylato) pyrrolidin-1-yl] diazen-1-ium-1,2-diolates 有权
    O-芳基化或O-糖基化的1-取代的二氮-1-烯-1,2-二醇酯和O 2取代的1 - [（2-羧基）吡咯烷-1-基]二氮-1- ium -1,2-二醇酯

    公开(公告)号：US06610660B1

    公开(公告)日：2003-08-26

    申请号：US09254301

    申请日：1999-05-03

    申请人： Joseph E. Saavedra ,  Larry K. Keefer ,  Aloka Srinivasan ,  William G. Rice ,  Xinhua Ji ,  Christian Bogdan

    发明人： Joseph E. Saavedra ,  Larry K. Keefer ,  Aloka Srinivasan ,  William G. Rice ,  Xinhua Ji ,  Christian Bogdan

    IPC分类号： C07D29522

    CPC分类号： C07D213/64 ,  C07C291/08 ,  C07D207/16 ,  C07D239/34 ,  C07D295/30 ,  C07H19/06 ,  C07H19/16

    摘要： Diazeniumdiolates, wherein the N1 position is substituted by an inorganic or organic moiety and the O2-oxygen is bound to a substituted or unsubstituted aromatic group, are provided. Also provided are O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates (O2-glycosylated diazeniumdiolates) and O2-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates (1-[(2-carboxylato)pyrrolidin-1-yl]diazeniumdiolates). The O2-aryl diazeniumdiolates are stable with respect to the hydrolytic generation of nitric oxide in neutral to acidic solutions and generate nitric oxide in basic or nucleophilic environments or microenvironments. Also provided are compositions, including pharmaceutical compositions, comprising such compounds and methods of using such compounds.

    摘要翻译： 二氮烯鎓二硫醇盐，其中N1位被无机或有机部分取代，并且O-氧与取代或未取代的芳族基团结合。 还提供了O-糖基化的1-取代的二氮嗪-1-铋-1,2-二醇酯（O 2 - 糖基化的二氮烯鎓二醇酯）和O 2取代的1 - [（2-羧基）吡咯烷-1-基]二氮-1- 1,2-二醇化物（1 - [（2-羧基）吡咯烷-1-基]二氮烯鎓二硫醇盐）。 相对于中性至酸性溶液中的一氧化氮的水解产生，氧芳基二氮烯鎓二硫醇盐是稳定的，并在碱性或亲核环境或微环境中产生一氧化氮。 还提供了包含这些化合物的药物组合物和使用这些化合物的方法的组合物。

    LINKED PURINE PTERIN HPPK INHIBITORS USEFUL AS ANTIBACTERIAL AGENTS
    16.
    发明申请
    LINKED PURINE PTERIN HPPK INHIBITORS USEFUL AS ANTIBACTERIAL AGENTS 有权

    公开(公告)号：US20130172285A1

    公开(公告)日：2013-07-04

    申请号：US13704857

    申请日：2011-06-01

    申请人： Genbin Shi ,  Gary X. Shaw ,  Xinhua Ji

    发明人： Genbin Shi ,  Gary X. Shaw ,  Xinhua Ji

    IPC分类号： C07H19/167 ,  G06F19/16 ,  C07D475/04

    CPC分类号： C07H19/16 ,  C07D475/04 ,  C07H19/167 ,  G06F19/16

    摘要： The disclosure provides linked purine pterin compounds and analogues thereof that are novel HPPK inhibitors. The HPPK inhibitors described herein are compounds and the pharmaceutically acceptable salts thereof of general Formula I The variables, e.g. A1 to A3, R1 to R4, L1, L2, B1, and B2 are described herein. Compounds and salts of Formula I bind to HPPK with high affinity and specificity. Pharmaceutical compositions containing an HPPK inhibitor of Formula I and methods of treating a bacterial infection in a patient by providing one or more HPPK inhibitors of Formula I to the patient are also provided. Processes and intermediates useful for preparing compounds of Formula I are also provided. Methods of using the disclosed compounds to guide the development of additional novel anti-bacterial agents are also provided.